Basal Health review
Basal’s GLP-One offers clinician-prescribed compounded tirzepatide in microdose and weight-loss plans. Those programs should be assessed separately rather than treated as interchangeable.
The verdict
Basal describes continued clinician contact and a patient portal, which matter more than its broad metabolic-wellness claims. For weight management, confirm the prescribed strength and treatment goal: a microdose offer does not establish the expected results of a conventional obesity-treatment regimen.
Disclosure: This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.
- Category
- GLP-1 telehealth
- Molecule
- Tirzepatide
- Form
- Injection
- Dose pricing
- Flat across doses
- From
- From $323.92/mo
- Prescription
- Required
- Compounded
- Yes — not FDA-approved
GLP-One is Basal’s tirzepatide care program, with clinical assessment, individualized dosing and progress follow-up. The site markets two distinct approaches, microdose and weight loss. Claims about metabolic optimization extend beyond a simple prescription service and deserve their own evidence.
Who writes the prescription, and what do they see?
The terms describe independent medical groups and professionals licensed where the patient is located. Basal itself provides the platform rather than practicing medicine. Clinical approval precedes charging under the homepage offer; a patient may be declined or directed to other care.
The portal brings treatment information, communication and follow-up together. Basal describes regular check-ins and monitoring, but the pages reviewed do not promise one consultation frequency for every patient. Ask whether any diagnostic testing is included and how an adverse reaction reaches the clinician.
What happens when the dose goes up?
Basal says its clinician selects a starting dose and adjusts treatment according to response. Its microdose and weight-loss pathways should not be compared solely on their shared ingredient. Request your actual dose range, refill instructions and plan for pauses before enrolling.
What the price includes
The advertised introductory period differs from continuing treatment, and billing repeats every four weeks. That creates more charges over a year than calendar-month billing. The site says the price holds across doses and that there is no membership fee; confirm which GLP-One plan that offer covers.
What it claims, and what it cites
GLP-One is described as compounded tirzepatide, not an FDA-approved finished medicine. Basal acknowledges that distinction. Published trials of approved tirzepatide products cannot establish the quality of a particular compounded shipment or validate all microdosing claims.
Where it holds up, and where it does not
- Strength: Charging follows clinical approval
- Strength: Patient portal and ongoing monitoring
- Strength: Four-week billing stated openly
- Limitation: Microdose evidence differs from standard obesity trials
- Limitation: Exact testing inclusions need confirmation
- Limitation: Four-week renewal can be mistaken for monthly billing
What the evidence says about this kind of treatment
The assessment above is about Basal Health. These are about the drugs it sells, and they are traced to the primary literature.
- Right for
- Someone seeking clinician-supervised tirzepatide who can distinguish the weight-loss plan from the microdose proposition.
- Wrong for
- A patient expecting FDA-approved branded medication or trial-level evidence for every claimed microdose benefit.
The evidence behind what Basal Health prescribes
These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation.
- Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?
In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points.
How Basal Health compares
| Seller | Who it suits | Go |
|---|---|---|
| SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | See SkinnyRx → |
| ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | See ShedRx → |
| RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | See RxSpan MD → |
More GLP-1 telehealth sellers reviews: Luma MedsLumen MedsLumiMedsLumoraLunaRxLVNG RX
Sponsored alternative
SkinnyRx
Readers choosing tirzepatide, the one line with a published standing rate
Check SkinnyRx availability →Frequently asked
- Is GLP-One an FDA-approved brand?
- No. Basal describes a compounded tirzepatide program and states that compounded products are not FDA approved.
- Does four-week billing mean twelve annual charges?
- No. Four-week supply cycles recur thirteen times in fifty-two weeks. Review the recurring amount rather than comparing only the introductory period.
- Is Basal Health expensive compared with other GLP-1 telehealth sellers?
- Basal Health publishes a starting figure of $323.92/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Basal Health above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes.
Sources for this review
Provider information checked . Terms can change.